Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Antitussive drugs" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The narcotics codeine and hydrocodone, and several opioids or opioid-like drugs, including dextromethorphan and butorphanol, are commonly used in small animals. antitussive-bronchodilator combination. a common therapeutic combination used in the treatment of respiratory diseases in dogs and cats.
Large Substituent, Non-Phenolic Opioids
ActiveUS20070021457A1Excellent opioid bindingGood metabolic stabilityBiocideNervous disorderBenzazocineAnalgesic agents
8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. One embodiment is the subgenus of biphenylethyl compounds:
Owner:RENESSELAER POLYTECHNIC INST
Sulfonamide compound as well as preparation method and application thereof
ActiveCN113773300AImprove securityStrong inhibitory activityOrganic chemistryAntipyreticDiseaseMetabolite
The invention discloses a sulfonamide compound as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The structure of the sulfonamide compound is shown as a formula I in the specification. The invention also discloses a preparation method of the compound as shown in the formula I. The invention provides application of a compound as shown in the formula I or a salt, a solvate, an allomer, a metabolite, nitrogen oxide and a prodrug of the compound in preparation of drugs for treating or preventing P2X3 and / or / P2X2 / 3 receptor related diseases. The sulfonamide compound provided by the invention has almost no influence on the taste of mice, and has a significant statistical difference from a positive control drug gefapixant. The antitussive effect strong positive drug has an antitussive effect time obviously prolonged compared with that of a contrast 1 compound, and the inhibitory activity of the antitussive drug pair on P2X3 is superior to that of the contrast 1 compound and the positive control drug gefapixant.
Owner:CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
InactiveUS6303632B1Reduce adverse effectsUseful in treatmentBiocideOrganic chemistryMotion sicknessWhole body
Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant / antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and / or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.
Owner:SEPACOR INC
Novel method for resolving 1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline through enzyme catalysis
The invention relates to a method for resolving 1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline through enzyme catalysis dynamic kinetics. Specifically, the invention provides a method for resolving 1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline racemate into a single configuration product (S)-1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline through dynamic kinetics and by utilizing cyclohexane oxidase and a mutant thereof, wherein (S)-1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline is a key intermediate for synthesizing the central antitussive drug dextromethorphan. The method has the outstanding characteristics of high yield, good stereoselectivity, mild reaction conditions and the like.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Methods for treating disorders using norastemizole in combination with other active ingredients
InactiveUS6458809B1Reduce adverse effectsUseful in treatmentBiocideAnimal repellantsDiseaseAntiinflammatory drug
Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant / antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and / or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.
Owner:SEPACOR INC
Loratadine oral compound medication composition
InactiveCN101015519AOrganic active ingredientsPharmaceutical delivery mechanismAntitussive drugsDrug effect
This invention relates to an orally adminstered compound Chinese medicinal composition of loratadine for treating cough. The composition comprises quick-release part containing loratadine and slow-release part containing centrum antitussive drug, wherein the centrum antitussive drug is preferably dextromethorphan. The invention maintains the quick and long lasting action of loratadine or desloratadine, overcomes the quick releasing and short action on relieving cough of dextromethorphan, slow releases dextromethorphan, and maintains the drug effect to arrive the purpose of relieving cough for a long time.
Owner:CHONGQING PHARMA RES INST
Novel method for synthesizing key intermediate of dextromethorphan through enzyme catalysis asymmetric synthesis
ActiveCN110628841ASimple process routeMild reaction conditionsFermentationAntitussive AgentDextromethorphan
The invention discloses imine reductase AtIR(WP_027931121.1) derived from Amycolatopsis thermoflava, imine reductase StIR(WP_023587323.1) derived from Streptomyces thermolilacinus, imine reductase PmIR(WP_091804541.1) derived from Prauserella marina, imine reductase SmIR(WP_020496004.1) derived from Sciscionella marina, imine reductase AaIR(WP_020635634.1) derived from Amycolatopsis alba or iminereductase ShIR(SHE96216.1) derived from Streptoalloteichus hindustanus, and the imine reductase is adopted as a biocatalyst for preparing a key intermediate (S)-1-(4-methoxy benzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline of a central antitussive, namely dextromethorphan. A 5-50g / L substrate can be catalyzed by using corresponding imine reductase, the conversion rate is greater than 99%, and the method has remarkable characteristics of being high in yield, good in stereoselectivity, mild in reaction condition, and the like.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Preparation process for key intermediate 1-(4-methoxyl)benzyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer) of dextromethorphan hydrobromide serving as cough relieving medicine
ActiveCN102219737ALow costSimple and safe operationOrganic chemistryIsoquinolineDextromethorphan Hydrobromide
The invention discloses a preparation process for a key intermediate 1-(4-methoxyl)benzyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer) of dextromethorphan hydrobromide serving as a cough relieving medicine, which comprises the following steps of: performing acylation reaction to obtain 1-(4-methoxyl)benzyl-2-alkylacyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (laevo isomer); and racemizing under the alkaline condition to obtain 1-(4-methoxyl)benzyl-2-alkylacyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer); and hydrolyzing under the alkaline condition to obtain the 1-(4-methoxyl)benzyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer). The process aims to overcome the defect of the synthetic process and reduce cost, so that the process is simply and safely operated, the industrial production is qualified, and the yield of products is between 55 and 69 percent.
Owner:JIANGSU BAOZONG & BAODA PHARMACHEM
Pharmaceutical composition containing Herba Lopatheri
InactiveCN103142870AIncrease varietyMeet clinical needsRespiratory disorderPlant ingredientsPharmaceutical drugEfficacy
The invention belongs to the technical field of medicine, and discloses an antitussive and a preparation method thereof. The medicament is prepared from the Herba Lopatheri, mulberry bark and loquat leaves. The medicament can be prepared into any clinically or pharmaceutically acceptable dosage form, preferably oral preparations. The medicament has efficacies of clearing lung, eliminating phlegm, and relieving sore throat and cough, and can be used for treating various cough, throat itch and pain.
Owner:史克勇
Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles
InactiveCN103893197ASolve the syndromes of combined injury symptomsOrganic active ingredientsAntipyreticDiseaseNaringin
The invention discloses application for a natural plant extract and monomers thereof in preparation for a medicine or a healthcare product preventing and treating respiratory injuries due to PM2.5 particles. The extract and the monomers thereof are a naringin-containing natural plant extract and the naringin monomers thereof. The application is exact in curative effect on the symptoms of cough, phlegm, asthma, airway inflammation and the like due to PM2.5 particles, high in safety, obviously superior to the single effect of clinically common cough-relieving medicines, phlegm-dispelling medicines, antiasthmatic medicines and anti-inflammatory medicines at present, and capable of solving the disease of the compound occurrence of various respiratory injury symptoms due to the pollution of PM2.5 particles.
Owner:苏薇薇
Method for preparing high purity dimemorfan and phosphate
InactiveCN101759642AAvoid irremovable shortcomingsHigh purityOrganic chemistryRespiratory disorderDistillationSolvent
The invention discloses a method for preparing high-purity dimemorfan and phosphate, relating to a new method for preparing and purifying raw material dimemorfan of an antitussive drug and a relative intermediate. The invention aims to avoid high vacuum degree distillation operation in the preparation of an US3786054 step five intermediate (2-(p-methylbenzyl)-octahydro isoquinolined-(+)tartrate) so as to avoid the disadvantage that individual impurity can not be removed through column separation. The step five intermediate with high purity and high yield is obtained by using acetone and the like as solvents to recrystallize cyclized reaction mixture.
Owner:北京利乐生制药科技有限公司
Licorice flavonoids antitussive and application thereof
InactiveCN101524397ASignificant antitussive effectAddressing the lack of strong non-narcotic cough suppressantsRespiratory disorderFood preparationDiseaseChronic cough
The invention provides an application of licorice flavonoids in preparing antitussives for treating acute and chronic cough caused by a plurality of reasons. The related acute and chronic cough comprises cough symptoms caused by various diseases such as acute and chronic tracheitis, asthma, chronic obstructive disease of lung, idiopathic pulmonary fibrosis, tuberculosis, bacterial pneumonia, bronchiectasis and the like. The licorice flavonoids extracted from liquorice proves to have very strong effect in preventing cough according to pharmacological tests; drug potency thereof is similar to the drug potency of codein in narcotic antitussive; the function mechanism analyses indicate that the licorice flavonoids plays the role of preventing cough through the non-narcotic nerve centre. In addition, the licorice flavonoids extracted from natural plants can also be prepared into health food. The invention solves the problem that the non-narcotic potent antitussives are badly needed, provides a non-narcotic potent antitussives which has fine social and economical benefits.
Owner:ZHEJIANG UNIV
Dextromethorphan hydrobromide chewable tablet and preparation method thereof
The invention belongs to the technical field of medicinal preparations, and discloses dextromethorphan chewing gum tablets and an industrially applicable preparation method thereof. The preparation is delivered through a chewing process, so that the defects of the marketed products at present can be overcome, and the tablets have the advantages of no need of water for taking, convenience in taking, good mouthfeel, less adverse effects, quick response, capability of eliminating thirst and the like. The dextromethorphan chewing gum tablets prepared by the invention are mainly used for dry coughand are suitable for cold, acute or chronic bronchitis, bronchial asthma, faucitis, phthisis and cough during other upper respiratory tract infections. The dextromethorphan chewing gum tablets provided by the invention have the advantages of simple preparation process, low cost, easiness in control and easiness for industrial production.
Owner:CHONGQING MEDICAL UNIVERSITY
Pharmaceutical composition and technique of preparing the same
InactiveCN101176730AGood choiceSignificant antitussive effectOrganic active ingredientsSolution deliveryDiseasePseudoephedrine
The invention provides a drug composition with the active components of levodropropizine, guaifenesin and pseudoephedrine or acceptable salts on the drugs and a preparation method, which is used for treating nasopharynx mucosa hyperemia, nasal obstruction, sneeze, snivel caused by cold and other diseases, cough and expectoration and other symptoms caused by bronchitis. Compared with the common used centrally antitussive drugs on market, the peripherally antitussive drugs of levodropropizine adopted by the invention have the advantages of obvious antitussive effect and less adverse reaction.
Owner:朱志宏
Condensed ring compound and use thereof
InactiveUS20100234368A1Increased airway hyperreactivityImprove respiratory functionOrganic active ingredientsOrganic chemistryDiseaseBronchial epithelium
Owner:ONO PHARMA CO LTD
Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
InactiveUS20100280059A1Same effectResists and diversionBiocideDispersion deliveryDecongestantAllergy
The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and / or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and / or decongestant.
Owner:ATTKISSON ELIZABETH E
Antitussive preparation
InactiveCN103142828AIncrease varietyMeet clinical needsRespiratory disorderPlant ingredientsFritillaria thunbergiiEfficacy
The invention belongs to the technical field of medicine and discloses an antitussive preparation and a preparation method. The preparation is prepared from Pinellia Tuber, mulberry bark, Zhejiang fritillaria bulb, loquat leaves and balloonflower root, and can be prepared into any clinical or pharmaceutically acceptable dosage forms, preferably oral preparation. The preparation has efficacies of clearing lung, eliminating phlegm, and relieving sore throat and a cough, and can be used for treating various cough and throat itch and pain.
Owner:史克勇
Paracetamol and dihydrocodeine tatrate tablet and preparation method thereof
InactiveCN103860557ARapid oral absorptionHas analgesiaOrganic active ingredientsAntipyreticCelluloseEfficacy
The invention discloses a component ratio and a preparation method of a paracetamol and dihydrocodeine tatrate tablet. The preparation method comprises the following steps: adding auxiliary materials comprising pregelatinized starch, lactose, hydroxypropyl cellulose, HPMC, sodium carboxymethyl starch and magnesium to a prescription dose of main components comprising stearate dihydrocodeine tartrate and paracetamol, carrying out balanced mixing, granulating, drying, finishing, mixing, tabletting, and packaging the obtained material in an aluminum plastic. The tablet has analgesic, antipyretic and antitussive effects, has the advantages of fast efficacies and effectiveness, long action time, good safety, variety of curative effects, reduction of the occurrence of untoward effects, and very extensive clinical application, and is worthy of popularization and application.
Owner:FUJIAN MINGLONG PHARMA
Dextromethorphan extended release pharmaceutical composition
ActiveUS20210023073A1Easy to swallowSimple manufacturing processOrganic active ingredientsCoatingsControl releasePharmaceutical medicine
The invention is directed to pharmaceutical compositions comprising dextromethorphan and methods of use thereof. Formulations of the present invention include dextromethorphan or a pharmaceutically acceptable salt thereof in a sustained release formulation comprising a controlled release agent. Formulations of the present invention include a core tablet, optionally an active coating and, optionally a film coating. The pharmaceutical compositions may be used as an antitussive, and the invention further relates to the treatment of cough in a patient in need thereof.
Owner:L PERRIGO
Benpipralin compound preparation for treating cough and preparation method of benpipralin compound preparation
InactiveCN114522163ALower metabolismIncrease blood concentrationOrganic active ingredientsDigestive systemEnzyme Inhibitor AgentPharmaceutical Aids
The invention discloses a benazolin compound preparation for treating cough and a preparation method of the benazolin compound preparation. The compound preparation comprises the following components: benpipralin and cimetidine in a ratio of (0.01-0.03): (0.1-0.3). The raw material medicines in corresponding parts are taken, proper auxiliary materials are added according to corresponding preparation methods of pharmaceutics, and the raw material medicines can be respectively prepared into dosage forms such as tablets, capsules, solutions, syrup, dry suspensions or granules. Benpipralin is a peripheral non-addictive cough relieving medicine and is mainly used for relieving cough caused by various reasons. The cimetidine is a histamine H2 receptor impedance agent, is a hepatodrug enzyme inhibitor, and can inhibit the activity of hepatodrug enzyme and slow down the metabolism of benpipralin, so that the blood concentration of benpipralin is improved, and the curative effect of benpipralin is enhanced; and the cimetidine alleviates the stimulation of the benpipralin to the stomach by inhibiting gastric acid secretion, and reduces the gastrointestinal tract side effect of the benpipralin.
Owner:徐娴娴
Preparation method of animal model for bronchial allergic cough
ActiveCN112889745AEfficiently obtainedScreening platform is goodCompounds screening/testingAnimal husbandryAntiallergic drugsUse medication
The invention relates to an animal model for bronchial allergic cough induced by histamine and citric acid. The animal model for the histamine sensitized and citric acid induced cough is designed in combination with the onset characteristics and rules of bronchial allergic cough, the animal model has a large therapeutic window, both traditional antiallergic drugs and antitussive drugs can play a good therapeutic role, and medication conditions of the animal model are consistent with medication conditions of clinically related patients. Therefore, the animal model can be used for evaluating and screening related drugs.
Owner:澎立生物医药技术(上海)股份有限公司
Preparation process for key intermediate 1-(4-methoxyl)benzyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer) of dextromethorphan hydrobromide serving as cough relieving medicine
ActiveCN102219737BLow costSimple and safe operationOrganic chemistryIsoquinolineDextromethorphan Hydrobromide
The invention discloses a preparation process for a key intermediate 1-(4-methoxyl)benzyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer) of dextromethorphan hydrobromide serving as a cough relieving medicine, which comprises the following steps of: performing acylation reaction to obtain 1-(4-methoxyl)benzyl-2-alkylacyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (laevo isomer); and racemizing under the alkaline condition to obtain 1-(4-methoxyl)benzyl-2-alkylacyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer); and hydrolyzing under the alkaline condition to obtain the 1-(4-methoxyl)benzyl-1,2,3,4,5,6,7,8-octahydro isoquinoline (mixed isomer). The process aims to overcome the defect of the synthetic process and reduce cost, so that the process is simply and safely operated, the industrial production is qualified, and the yield of products is between 55 and 69 percent.
Owner:JIANGSU BAOZONG & BAODA PHARMACHEM
Compound chemical medicine with antitussive and phlegm-eliminating action and its preparation technology
The invention provides a compound chemical medicament with cough relieving and expectorant effects and its preparation method, especially relates to a medicament composed of levodropropizine and guaiphenesin as active ingredient and pharmically receivable adjuvant and its production technology. Levodropropizine adopted in the invention is peripheral antitussive. Compared with present conventionalcentral antitussive, it has good antitussive effect and less adverse reaction.
Owner:太阳升(亳州)生物医药科技有限公司
Antitussive preparation
InactiveCN103142791AIncrease varietyMeet clinical needsRespiratory disorderPlant ingredientsThroatPinellia
The invention belongs to the technical field of medicine, and discloses an antitussive medicine and a preparation method thereof. The medicament is prepared from bitter apricot kernel, balloonflower root, pinellia tuber and puffball fruiting body. The medicament can be prepared into any clinical or pharmaceutically acceptable dosage forms, preferably oral preparation. The medicament has efficacies of clearing lung, eliminating phlegm, and relieving sore throat and a cough, and can be used for treating various cough and throat itch and pain.
Owner:史克勇
Pharmaceutical formulation
PendingUS20220079937A1Inorganic non-active ingredientsEther/acetal active ingredientsDecongestantPharmaceutical medicine
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.
Owner:RB HEALTH US LLC
A preparation method of an animal model of bronchial allergic cough
ActiveCN112889745BEfficiently obtainedScreening platform is goodCompounds screening/testingAnimal husbandryAntiallergic drugsUse medication
The present invention relates to an animal model of histamine and citric acid-induced bronchial allergic cough. Combining with the onset characteristics and rules of bronchial allergic cough, an animal model of histamine sensitization and citric acid-induced cough is designed, and its therapeutic window is relatively large. , Traditional antiallergic drugs and antitussive drugs can play a good therapeutic effect, which is consistent with the clinical use of relevant patients. Therefore, this animal model can be used for the evaluation and screening of related drugs.
Owner:澎立生物医药技术(上海)股份有限公司
Preparation method of pure vegetoanimal antitussive liquid
InactiveCN112516192ASimple preparation stepsExtensive sterilizationAntibacterial agentsAntimycoticsBiotechnologyChemical reaction
The invention discloses a preparation method of pure vegetoanimal antitussive liquid. The preparation method comprises the following steps: mixing and adding raw materials (65.67% of acetic acid, 0.17% of porcine gall powder, 8.33% of flos chrysanthemi indici, 8.33% of fructus xanthii , 0.8% of pulvis fumi carbonisatus, 8.33% of herba menthae and 8.3% of herba taraxaci) into an acetic acid solution, putting the mixture in a basement at 25 DEG C or below for one year or more to make the mixture undergo a sufficient chemical reaction, and then performing distilling to obtain the antitussive liquid with a very obvious antitussive effect. it is determined that the acidity is PH3 or below after the antitussive liquid stands in a storehouse for three months, and then a finished-product antitussive drug is obtained. The preparation method has simple preparation steps, and compared with a traditional Chinese medicine, the antitussive liquid can kill broader bacteria, has a stronger bacteria killing effect, and is efficient and free of side effects.
Owner:成都瑞哲思科技有限公司
Application of biotransformation bear bile powder in preparation of antitussive medicine
ActiveCN109125352BProlonged cough latencyLess frequent coughingBird material medical ingredientsRespiratory disorderCough FrequencyAntitussive drugs
The invention discloses the application of biotransformation bear bile powder in preparing antitussive medicine. The present invention studies the antitussive efficacy of the biotransformed bear bile powder, and the experimental results show that the biotransformed bear bile powder can prolong the cough incubation period and reduce the cough frequency of mice induced by ammonia water, thus revealing The application of biotransformed bear bile powder in the preparation of antitussive drugs was studied.
Owner:SHANGHAI KAIBAO PHARMA
Dextromethorphan chewing gum tablets and preparation method thereof
ActiveCN102258489BOrganic active ingredientsPill deliveryBronchial epitheliumObstructive chronic bronchitis
Owner:CHONGQING MEDICAL UNIVERSITY
Application of marmesine in preparation of cough relieving medicine
ActiveCN103054854AWiden the field of choiceSignificant antitussive effectRespiratory disorderHeterocyclic compound active ingredientsPharmacySide effect
The invention discloses application of marmesine in preparation of a cough relieving medicine. According to the invention, marmesine has an obvious cough relieving effect and is found for the first time; furthermore, the cough relieving manner is a non-central cough relieving manner; side effects of conventional central cough relieving medicines in the aspect of a central nervous system are avoided; the invention provides a brand-new selection and idea for current cough treatment, expands selection fields of cough relieving medicines and also makes a contribution to development in the technical field; the marmesine disclosed by the invention is a compound having a definite chemical structure; for pharmacy, the marmesine can be quantitatively fed and is used for preparing modern dosage forms; and furthermore, the marmesine is high in medicine safety and has a potential to develop the cough relieving medicine.
Owner:SUN YAT SEN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com